Collegium Pharmaceutical, Inc. Proceeds from Sale and Maturity of Marketable Securities
Collegium Pharmaceutical, Inc. (COLL) reported Proceeds from Sale and Maturity of Marketable Securities of $20.01 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-05-07
- Collegium Pharmaceutical, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $20.01M, a 17.63% increase year-over-year.
- Collegium Pharmaceutical, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $19.84M, a 24.20% increase year-over-year.
- Collegium Pharmaceutical, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $14.56M, a 50.49% decline year-over-year.
- Collegium Pharmaceutical, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-06-30 was $13.76M, a 46.37% decline year-over-year.
- Collegium Pharmaceutical, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $65.18M, a 29.62% decline from fiscal 2024.
- Collegium Pharmaceutical, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $92.60M, a 320.92% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $22.00M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-03-31 | $20.01M 10-Q · filed 2026-05-07 | $39.85M derived: sum of 2 quarters · filed 2026-05-07 | $54.41M derived: sum of 3 quarters · filed 2026-05-07 | $68.17M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $19.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $34.41M derived: sum of 2 quarters · filed 2026-02-26 | $48.17M derived: sum of 3 quarters · filed 2026-02-26 | $65.18M 10-K · filed 2026-02-26 |
| 2025-09-30 | $14.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $28.33M derived: sum of 2 quarters · filed 2025-11-06 | $45.33M 10-Q · filed 2025-11-06 | $61.31M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | $13.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $30.77M 10-Q · filed 2025-08-07 | $46.74M derived: sum of 3 quarters · filed 2026-05-07 | $76.16M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | $17.01M 10-Q · filed 2026-05-07 | $32.98M derived: sum of 2 quarters · filed 2026-05-07 | $62.40M derived: sum of 3 quarters · filed 2026-05-07 | $88.06M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $45.40M derived: sum of 2 quarters · filed 2026-02-26 | $71.05M derived: sum of 3 quarters · filed 2026-02-26 | $92.60M 10-K · filed 2026-02-26 |
| 2024-09-30 | $29.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $55.08M derived: sum of 2 quarters · filed 2025-11-06 | $76.63M 10-Q · filed 2025-11-06 | $92.63M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $25.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $47.21M 10-Q · filed 2025-08-07 | $63.21M derived: sum of 3 quarters · filed 2026-02-26 | $69.21M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $21.55M 10-Q · filed 2025-05-08 | $37.55M derived: sum of 2 quarters · filed 2026-02-26 | $43.55M derived: sum of 3 quarters · filed 2026-02-26 | $43.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.00M derived: sum of 2 quarters · filed 2026-02-26 | $22.00M derived: sum of 3 quarters · filed 2026-02-26 | $22.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.00M derived: sum of 2 quarters · filed 2024-11-07 | $6.00M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |